Navigation Links
Enox Biopharma, Inc. Will Be Granted its Foundation Patent
Date:8/22/2011

VANCOUVER, British Columbia, Aug. 22, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, today announced that it has received a notice of allowance from the US Patent Office that its patent application entitled "Antimicrobial Gas-Releasing Ear Drainage Tubes" has been approved and a patent will granted.

This patent was the first applied for by Enox and is the foundation patent of the company. The notice of allowance for this patent underscores the novelty of Enox's technology which utilizes nitric oxide gas embedded into polymers as an antimicrobial to prevent hospital acquired infections. Nitric oxide is well recognized as an ideal antimicrobial agent that is highly effective yet free from the drug resistance issues that have resulted from excessive antibiotic use. Additional patent applications, which are under review in the United States and in countries around the world, expand the use of antimicrobial gas releasing technology to virtually any polymer-based medical device.

"This is a very significant patent for Enox. Not only does it solidify our intellectual property portfolio, it is rigorous external validation of our technology being the first of its kind. With our foundation patent issued, the probability of our other intellectual property applications being successful is increased," stated Enox CEO, John Rewcastle, Ph.D. "Nitric oxide emitting medical devices have a unique potential to reduce hospital acquired infections which are a global problem costing tens of billions of dollars annually. The issuance of this patent further ensures Enox is the only company that can create such devices."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D., CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
2. Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices
3. PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015
4. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
5. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
6. Plato BioPharma, Inc Appoints New Board Member
7. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
9. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... in the ECG Cables And ECG Leadwires Market owing to ... devices. On the other hand, the Asia-Pacific ... rate during the forecast period. The market players ... plc ( Ireland ), Koninklijke Philips N.V. ( ... ( China ), held major share of the ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 /PRNewswire/ ... research report "In Vitro Diagnostics/IVD Market by Product ... Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious ... the global market is valued at USD 60.22 ... grow at a CAGR of 5.5% during the ...
(Date:12/2/2016)... On Thursday, December 1st 2016, ... research, development and innovation in the biopharmaceutical industry at ... in the presence of Sergey Tsyb, Vice Minister of ... , Natalia Sanina, First Vice Chairman of the ... of Roszdravnadzor, National Service of Control in Healthcare, Sergey ...
Breaking Medicine Technology:
(Date:12/2/2016)... Milford, NJ (PRWEB) , ... December 02, 2016 , ... ... Nothing Water has some unique properties including its unmatched natural purity of just 6 ... as clean and crisp. , Nothing Water has been available in several ShopRite and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
(Date:11/30/2016)... PALMYRA, Wisconsin (PRWEB) , ... November 30, 2016 ... ... inclusion in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of ... consecutive year on the list, having ranked from 2008-2016. In addition, Standard Process ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):